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Abstract
Patients with heterotaxy have characteristic cardiovascular malformations, abnormal arrangement of their visceral organs,
and midline patterning defects that result from abnormal left-right patterning during embryogenesis. Loss of function of
the transcription factor ZIC3 causes X-linked heterotaxy and isolated congenital heart malformations and represents one of
the few known monogenic causes of congenital heart disease. The birth incidence of heterotaxy-spectrum malformations is
significantly higher in males, but our previous work indicated that mutations within ZIC3 did not account for the male over-
representation. Therefore, cross species comparative sequence alignment was used to identify a putative novel fourth exon,
and the existence of a novel alternatively spliced transcript was confirmed by amplification from murine embryonic RNA
and subsequent sequencing. This transcript, termed Zic3-B, encompasses exons 1, 2, and 4 whereas Zic3-A encompasses
exons 1, 2, and 3. The resulting protein isoforms are 466 and 456 amino acid residues respectively, sharing the first 407
residues. Importantly, the last two amino acids in the fifth zinc finger DNA binding domain are altered in the Zic3-B isoform,
indicating a potential functional difference that was further evaluated by expression, subcellular localization, and
transactivation analyses. The temporo-spatial expression pattern of Zic3-B overlaps with Zic3-A in vivo, and both isoforms are
localized to the nucleus in vitro. Both isoforms can transcriptionally activate a Gli binding site reporter, but only ZIC3-A
synergistically activates upon co-transfection with Gli3, suggesting that the isoforms are functionally distinct. Screening 109
familial and sporadic male heterotaxy cases did not identify pathogenic mutations in the newly identified fourth exon and
larger studies are necessary to establish the importance of the novel isoform in human disease.
Citation: Bedard JEJ, Haaning AM, Ware SM (2011) Identification of a Novel ZIC3 Isoform and Mutation Screening in Patients with Heterotaxy and Congenital
Heart Disease. PLoS ONE 6(8): e23755. doi:10.1371/journal.pone.0023755
Editor: Giuseppe Novelli, Tor Vergata University of Rome, Italy
Received April 13, 2011; Accepted July 24, 2011; Published August 17, 2011
Copyright:  2011 Bedard et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grants from the NIH (HL088639) to SMW and an American Heart Association Postdoctoral Fellowship Research Award,
Great Rivers Affiliate (0725539B) to JEJB. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the
manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: stephanie.ware@cchmc.org
¤ Current address: Adams State College, Alamosa, Colorado, United States of America
Introduction
Mutations in the gene encoding zinc finger of the cerebellum
protein 3 (ZIC3; NM_003413.3) result in heterotaxy and can cause
isolated congenital heart defects (CHD). Clinical features of
heterotaxy, or situs ambiguus, include complex CHDs and low
survival rates in affected individuals. There is a spectrum of typical
cardiac defects in heterotaxy, including dextrocardia, transposition
of the great arteries, and double outlet right ventricle, among
others [1,2].
ZIC3, a member of the GLI superfamily of transcription factors,
contains five highly conserved C2H2-type zinc finger domains that
span over one-third of the protein and are required for DNA-
binding and subsequent transcriptional activation [3,4,5,6,7].
Previously, ZIC3 was shown to bind and activate transcription
at a Gli consensus binding sequence [3,6] as well as a distinct cis-
element in the Nanog promoter [7]. The zinc finger DNA binding
domains of ZIC3 are important in performing other complex
functions as well, such as binding to co-proteins and directing
proper cellular trafficking during development [6,8,9,10].
Although ZIC3 is critical for neural, neural crest, mesoderm,
and left-right axis development, its precise functions during
development and body pattern formation are not known
[2,11,12,13,14,15]. Previous work from our lab and others has
shown that mutations and deletions of ZIC3-A result in
cardiovascular malformations and visceral situs anomalies
[10,16,17,18,19,20,21] due to loss of function. Deletion of Zic3
in mouse recapitulates the phenotypes found in patients with
ZIC3-A mutations [2,21], providing additional evidence for its role
in left-right patterning.
It is estimated that up to 74% of all human genes express
multiple mRNAs by alternative splicing of their pre-mRNAs
[2,22]. Alternative splicing is an effective mechanism that
facilitates an increase in mRNA and protein diversity without
increasing overall gene numbers. Here we identify and character-
ize ZIC3-B, a novel alternative isoform of ZIC3, hereafter called
ZIC3-A; compare the abilities of the two isoforms to activate
transcription at the Gli binding site, a known target; and screen for
mutations within the newly identified alternative exon in patients
with heterotaxy and CHD.
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Ethics Statement
The Institutional Animal Care and Use Committee of
Cincinnati Children’s Hospital approved this study (IACUC
protocol number 0C07054). Anonymized human skin fibroblast
cells were analyzed. These cells are considered non-human
subject research by the Cincinnati Children’s Hospital Institu-
tional Review Board. Patient samples were originally collected
under an IRB approved protocol from Baylor College of
Medicine. De-identified samples were provided for this study
and are categorized as non-human subject research. The
Cincinnati Children’s Hospital Institutional Review Board has
approved this study.
Cell culture conditions and transfections
NIH/3T3 and HeLa cells were obtained from the American
Type Culture Collection. All cells were grown in high glucose
Dulbecco’s Modified Eagle’s Medium (Gibco) and supplemented
with 10% fetal bovine serum (Gibco). For each experiment, cells
were counted using a hemocytometer and plated to achieve 50%
density the following day for transfections. Cells were transfected
using Lipofectamine and Plus reagents (Invitrogen) or Fugene
HD (Roche) for 24–48 hours as per the manufacturer’s
recommendations.
RNA isolation, reverse-transcriptase (RT)-PCR, and
real-time PCR
RNA was extracted from C57BL/6 mouse tissues and cultured
cells using Trizol reagent (Invitrogen) according to the manufac-
turer’s recommendations. RNA was quantified using a Biomate3
spectrophotometer (Thermo Electron Corporation). RT-PCR was
performed using the Titan One Tube RT-PCR System (Roche) as
per manufacturer’s recommendations, using 50 ng of total RNA as
template. Amplification of the entire murine Zic3-A open reading
frame was performed using the following primer pair: mZic3–
59UTR-Forward – 59-GCC TGC ACC CTT GCT CAC TTC-39
and mZic3–39UTR-Reverse – 59-GGC CTC TTG CTT TAA
AAC TCC-39. Amplification of Zic3-B exon 2-4 region was
performed using the primer pair: Zic3-Exon2-EcoRI-Forward: 59-
TTT CAA ATG TGA ATT CGA AGG-39 and Zic3-B-ORF-
Reverse: 59-TCA GTA AAT CAT TTC TTG CAC A-39. The
following Zic3 oligonucleotide primers were used to differentiate
between murine isoforms by gel electrophoresis: Zic3 Forward –
59-AAG GCT GTG ACA GAC GGT TT-39; Zic3-A Reverse –
59-TTG TGG CTG GTG CTA GTT TG-39; and Zic3-B Reverse
–5 9-TTG CTG CAT ACC AAC GTC AG-39. The same primers
were used to amplify isoforms from cultured human cell RNA with
the exception of the Zic3-B reverse primer, which was substituted
with ZIC3-B Reverse 59-CTG GCT GCT GCA TAC CAA C-39.
Murine-specific b-actin oligonucleotides were: mActin-Forward:
59-TTC TTT GCA GCT CCT TCG TT-39 and mActin-
Reverse: 59-CTT CTC CAT GTC GTC CCA GT-39. Total
mRNA was converted into cDNA using the Transcriptor First
Strand cDNA Synthesis Kit (Roche) as per manufacturer’s
recommendations using the provided anchored-oligo (dT)18
primer.
Expression constructs
The mZic3-59UTR-F-mZic3-39UTR-R amplicon was TA-
cloned into the pGEM-T vector (Promega) and subsequently used
as a template for amplification of the Zic3-A open reading frame
region using the following primers containing KpnI restriction sites:
mZic3-A-ORF-Forward – 59-AAC AAC GGT ACC ATG ACG
ATG CTC CTG CAC G-39 and mZic3-A-ORF-Reverse – 59-
TTT TGG GGT ACC TCA GAC GTA CCA TTC GTT AAA
ATT G-39. The Zic3-A PCR product was subsequently digested
with EcoRI and KpnI restriction endonucleases and subcloned in-
frame into a pFLAG-CMV-2 expression vector (Sigma). Utilizing
a unique EcoRI restriction site in Zic3, the 39-region of Zic3-A was
replaced with the digested Zic3-B exon2-4 insert to create the
entire murine Zic3-B ORF. The Zic3-B ORF was then subcloned
in-frame into a pHM6 vector (Roche) in order to be comparable to
previously characterized HA-tagged wild-type and mutant (S43X)
ZIC3-A [3]. All expression constructs were verified by DNA
sequencing. For dual luciferase assays, a firefly luciferase-
expressing 12xGLIBS-luc [23] reporter and a renilla luciferase-
expressing pRL-TK reporter (Promega) were used. Flag-GLI1 and
Flag-GLI3 constructs were described previously [24,25].
Heterotaxy Cohort
Patients were ascertained on the basis of cardiovascular
malformations and were categorized as having classic heterotaxy
or CHD heterotaxy as described previously [10]. For the current
study, only samples from males were screened. Briefly, patients
with complex cardiovascular malformations and evidence of
Table 1. Cardiovascular Malformations in the CHD
Heterotaxy Group.
Classic Heterotaxy 60
CHD Heterotaxy
a 49
Cardiac position
levocardia 34
mesocardia 2
dextrocardia 13
Atria
Isomerism or inversion 2
ASD 2
AV canal or atresia 3
TAPVR or PAPVR 2
Ventricles
VSD 10
VI 4
Hypoplastic left ventricle 5
MA 3
Great Arteries
D-TGA 29
DORV 3
L-TGA 15
PS or PA 8
AS 1
CoA 9
aTen patients had isolated D-TGA. The remainder had multiple cardiovascular
malformations.
ASD, atrial septal defect; AV, atrioventricular; TAPVR, total anomalous
pulmonary venous return; PAPVR, partial anomalous pulmonary venous return;
VSD, ventricular septal defect; VI, ventricular inversion; MA, mitral atresia;
D-TGA, D-transposition of the great arteries; DORV, double outlet right
ventricle; L-TGA, L-transposition of the great arteries; PS, pulmonic stenosis; PA,
pulmonic atresia; AS, aortic stenosis; CoA, coarctation of the aorta.
doi:10.1371/journal.pone.0023755.t001
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were classified as classic heterotaxy. Patients were categorized as
having CHD heterotaxy if they had normal situs in other organs
and vasculature or if insufficient information was available to
determine extra-cardiac organ position. The cardiovascular
malformations ascertained were based on those described in the
Baltimore-Washington Infant Study. All patients had complex
defects with more than one abnormality of cardiac structure or
position with the exception of 10 patients that had isolated D-
transposition of the great arteries (TGA). Patients with situs
inversus totalis were not included. Table 1 summarizes the
cardiovascular malformations in the heterotaxy CHD group.
Mutation screening
All patient samples were analyzed for mutations in the coding
region of exon 4 and the splice acceptor site as described below.
Thirty of 109 patients had previously been analyzed by full
sequencing of ZIC3-A [10]. Patients that were not previously
sequenced for ZIC3-A underwent sequencing using primers
described previously [10]. Patient genomic DNA was isolated
and prepared by standard procedures. Amplification of DNA was
performed by PCR in reaction volumes of 20 mL containing the
following reagents: 2 mL of 10X Taq polymerase reaction buffer
(Fisher), 0.2 U Taq polymerase (Fisher), 0.2 nM of each
oligonucleotide primer, and 50 ng of genomic DNA template.
Oligonucleotide sequences were: ZIC3-EXON4-Forward: 59-AAG
AGG AAA TGT GGC CTG TTT-39 and ZIC3-EXON4-Reverse
59-CAC TTC AAG GTA ACA GAC ATC CA-39. Amplifications
were performed using standard PCR conditions and annealing at
55uC. DNA sequencing was performed on an ABI Prism 3730
sequencer and variants were identified using SeqMan Pro (DNA
Star) software followed by manual review.
Protein isolation, western blotting and
immunohistochemistry
Cells were washed in ice-cold PBS before the addition of lysis
buffer (3.0 mM EDTA, 1% Triton X-100, 0.1 mM sodium
orthovanadate, 1 mM phenylmethylsulfonyl fluoride) with prote-
ase (Roche) and phosphatase (Sigma) inhibitors. Whole cell lysate
was freeze-thawed and vortexed briefly, followed by centrifugation
at 4uC for 10 min to pellet cellular debris. Protein samples were
quantified by the method of Lowry et al. [26]. Samples were
electrophoresed on 10% Tris-Glycine mini gels (Invitrogen) using
the XCell SureLock Mini-Cell (Invitrogen) according to manu-
facturer’s recommendations. Gels were transferred to pre-soaked
Immuno-Blot PVDF membranes (Invitrogen) using the XCell II
Blot Module (Invitrogen). Western blots were blocked in 5% non-
fat dry milk in 1X PBST at room temperature for one hour. Anti-
ZIC3 C-terminal (C-13, catalog # SC-28156) and N-terminal (N-
19, catalog # SC-28154) polyclonal antibodies were purchased
from Santa Cruz Biotechnologies. Following overnight incubation
with primary antibodies, blots were washed three times, 10 min
each, in 1X PBST, followed by one hour incubation in 5% milk in
PBST with the appropriate HRP conjugated secondary antibody.
Figure 1. Cross species comparative sequence alignment. (A) Genomic alignment across 11 kb of human and murine DNA containing the
Zic3 gene. Known and putative Zic3 exons, untranslated regions (UTR) and non-coding sequences (CNS) are indicated. All exons are conserved at a
minimum 91% identity between human and murine sequences. (B) Sequence alignment of the putative exon 4 in human and mouse demonstrates
97% identity.
doi:10.1371/journal.pone.0023755.g001
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PBST before detection using ECL Plus Detection Reagent (GE
Healthcare) and autoradiography film (Denville Scientific).
Immunohistochemistry and subcellular localization assays were
performed as previously described [4]. The anti-FLAG antibody
was purchased from Stratagene (catalog # 200470-21).
Dual luciferase assay
Flag-GLI3, HA-ZIC3-A, HA-ZIC3-S43X, and HA-Zic3-B
constructs were co-transfected as indicated with the reporters
12xGLIBS-luc [23] and pRL-TK (Promega) into NIH/3T3 cells
using Fugene HD. Transactivation levels with human HA-ZIC3-A
and mouse HA-Zic3-A were previously shown to be identical and
Figure 2. Genomic structure and alternative splicing of Zic3. (A) Schematic depiction of the genomic structure of Zic3. Zic3-A consists of
exons 1, 2, and 3 while Zic3-B consists of exons 1, 2, and 4. Primer sites used for isoform specific amplification in exons 2–3 and exons 2–4 are
indicated. F = forward, R(-A) = reverse for Zic3-A, and R(-B) = reverse for Zic3-B isoforms. (B) Sequence alignment of exon 4 translation across
species. (*) identical, (:) functionally conserved or (.) semi-conserved amino acid residues are indicated. (C) Sequence alignment of murine Zic3-A and
Zic3-B protein isoforms. Zinc finger domains (ZF-1–5) are indicated by brackets. NLS regions are underlined and NES region is shaded in gray. The last
two amino acids in the fifth zinc finger domain that differ between the two isoforms are indicated in red. ZF, zinc finger.
doi:10.1371/journal.pone.0023755.g002
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with HA-ZIC3-S43X, a known patient mutation. Cell lysates were
harvested after 48 hours using Passive Lysis Buffer (Promega). A
Dual Luciferase Assay Kit (Promega) and a microplate luminom-
eter (Turner Biosystems) were used to measure luminescence from
cell lysates in triplicate, according to the manufacturer’s
recommendations. Firefly luciferase readings were normalized to
renilla luciferase readings, and ratios were normalized to a
Figure 3. Alignment of the coding sequences of Zic3-A and Zic3-B transcripts. The coding sequences of murine Zic3-A and Zic3-B were
aligned. Alternating exons are indicated by gray shading. The last exons aligned are exons 3 and 4 for Zic3-A and -B, respectively, demonstrating less
than 35% identity.
doi:10.1371/journal.pone.0023755.g003
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vectors with both reporters. Statistical difference between values
was determined by unpaired Student’s t-test, assuming unequal
variance, and differences were considered significant if the
resulting probability value was less than 0.05.
Results
Prediction of a novel Zic3 exon
According to current estimates, approximately 1% of sporadic
CHD and the majority of X-linked heterotaxy cases are caused by
mutations in ZIC3 in the human population. These results
indicate that, although there is a significant overrepresentation of
males affected with heterotaxy, it is not due only to mutations in
the currently identified form of ZIC3. This raised the possibility
that mutations in a previously unrecognized, alternatively spliced
form of ZIC3 might contribute to heterotaxy and CHD cases. To
investigate this hypothesis, genomic DNA fragments containing
ZIC3 were aligned and compared using mVista software (http://
genome.lbl.gov/vista/mvista/submit.shtml) to search for nucleo-
tide homology across species (Figure 1A) [27]. Regions of high
homology were also screened for consensus (AG) splice acceptor
sites. These analyses revealed a region that is 97% similar in
human and mouse (Figure 1B), located approximately 5 kb
downstream from the ZIC3 gene. Further in silico analyses
confirmed a potentially spliced ZIC3 mRNA (http://www.
ensembl.org – Transcript ID: ENST00000370606) [8,10]. The
predicted spliced form is identical to ZIC3 except for the last exon,
which, if expressed, would result in a protein with a unique
carboxy (C)-terminal region. An additional predicted ZIC3
isoform containing a truncation of 220 amino acids from the
amino (N)-terminus was also identified in silico, but was not further
investigated in this current study as it did not encompass a novel,
putative exon.
Murine Zic3 contains four exons that are alternatively
spliced
The gene structure of Zic3 is therefore comprised of a total of
four exons, of which exons 3 and 4 are alternatively spliced
(Figure 2A). Alignment of exons 3 and 4 demonstrates less than
35% identity between them (Figure 3), suggesting that exon 4
evolved independently and did not arise by a duplication and
divergence of exon 3.
Cross species conservation is a known feature of exon coding
regions. The translation of the novel mRNA sequence and cross-
species comparison further demonstrates that the coding region of
exon 4 is highly conserved in mammals (Figure 2B). This finding
provides additional evidence for the existence of a novel Zic3-B
protein isoform. The resulting protein isoforms are 466 and 456
amino acid residues respectively, sharing the first 407 residues.
Because of the extensive sharing of residues, many of the
important structural domains are identical in Zic3-A and Zic3-B
(Figure 2A and 2C). Zic3-A has five zinc finger domains, the first
four of which are encoded by exons 1 and 2. The fifth zinc finger
domain, encoded by exons 2 and 3, contains a nuclear localization
signal (NLS). Interestingly, Zic3-A and Zic3-B differ at the last two
amino acid residues of the fifth zinc finger domain (Figure 2C).
Because these last two amino acids are in an NLS region [8] and in
an alpha-helical region that is essential for DNA binding [28], the
function of the fifth zinc finger domain is most likely altered in the
Zic3-B isoform. The other two known NLS domains [8,29] and
the nuclear export signal (NES) domain [8] are intact in the Zic3-B
isoform (Figure 2C).
Developmental expression profile of Zic3-A and -B mRNA
In order to confirm the existence of an alternatively-spliced
exon in vivo, we designed isoform specific primers for murine
Zic3. Murine embryonic day (e)10.5 RNA served as the template
for RT-PCR, and products of the expected sizes for Zic3-A and
–B were amplified and sequenced, confirming the existence of
two distinct Zic3 mRNAs with unique 39 ends beginning
immediately after exon 2. RT-PCR was also used to examine
expression of both isoforms at e13 and 16, as well as in a panel
of adult tissues (Figure 4A and B). Transcripts of both isoforms
of Zic3 were detected at all three embryonic stages and in adult
brain tissue. Zic3 expression by RT-PCR has been reported in
murine heart tissue [30]. Upon extending PCR cycles (45–60)
we detected Zic3-A expression in murine e10.5 heart tissue, but
Figure 4. Comparative expression profile of Zic3-A and Zic3–B.
(A–B) Semi-quantitative RT-PCR results of Zic3 isoform specific mRNA
expression. (A) Developmental expression profile at E10.5, 13 and 16,
and (B) postnatal tissue specific expression profile. (C) Expression of
Zic3-A and -B mRNA in HEK293 and P19 cell lines. Approximate band
sizes in panels A and C are indicated by arrowheads. Upper =300 bp,
lower =200 bp. cer, cerebellum; mus, skeletal muscle; liv, liver; spl,
spleen; brn, brain without cerebellum; hrt, heart; kid, kidney; lng, lung;
-RT, control without reverse transcriptase.
doi:10.1371/journal.pone.0023755.g004
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isoforms were also detected in human embryonic kidney
(HEK293) and pluripotent murine teratocarcinoma (P19) cells
(Figure 4C).
Characterization of ZIC3-A and -B proteins
Expression of endogenous ZIC3-A and -B proteins was
investigated in both murine and human cell lines. We used
ZIC3 specific antibodies that recognize either the C-terminal or
N-terminal ends, exploiting the fact that the C-terminal antibody
will only recognize ZIC3-A and the N-terminal antibody will
recognize both forms (Figure 5 A–B). Using whole cell lysates of
NIH/3T3 mouse fibroblasts and Western analysis, we detected a
single ZIC3-A band with the C-terminal antibody and two bands
with the N-terminal antibody (Figure 5 C–D). Similar results were
observed with human fibroblasts (Figure 5 E–F). Taken together
with our RNA expression evidence, these data demonstrate the in
vivo expression of ZIC3-B at both the RNA and protein levels.
Therefore we conclude that ZIC3-B is a novel and distinct
isoform.
Previous in vitro investigations indicate that ZIC family proteins
localize to the nucleus. In order to investigate the subcellular
localization of the novel isoform, we performed immunohisto-
chemistry in HeLa cells after transfection with FLAG-Zic3-B
(Figure 6) and quantified subcellular localization as previously
described [4]. Zic3-B is found within the nucleus in approximately
98% of cells (Figure 6G), indicating that this novel isoform is
similar to other ZIC family members in its in vitro subcellular
localization.
ZIC3-A and –B differ in transcriptional activation ability
ZIC3-A has been previously shown to bind to the Gli consensus
binding sequence (GLIBS) in vitro by electrophoretic mobility shift
assay (EMSA), and it has also been shown to transcriptionally activate
luciferase reporters containing multiple, tandem GLIBS [3,6]. Zhu et
al. [3] showed by EMSA that the C-terminal region of ZIC3-A is
necessary for binding to the GLIBS and that mutations affecting the
C-terminus typically resulted in decreased transcriptional activation
of a GLIBS reporter, even when all of the zinc finger domains were
intact. As an additional control, a previously described ZIC3-S43X
mutant construct was used that encodes only the first 43 amino acids
of ZIC3, a region which is identical in both A and B isoforms and
which does not contain any zinc finger binding or NLS and NES
domains [3,8,29]. Because the C-terminal regions of ZIC3-A and –B
Figure 5. Expression of ZIC3-A and ZIC3-B isoforms in mammalian cells. (A) Anti-ZIC3 immunogen specific for C-terminus (C12), and (B) for
N-terminus (N19). Detection of endogenous ZIC3-A and –B expression in (C–D) murine NIH/3T3 and (E–F) human fibroblast whole cell lysate using
anti-ZIC3 C-terminus (C, E) or anti-ZIC3 N-terminus specific antibodies (D, F).
doi:10.1371/journal.pone.0023755.g005
Figure 6. Subcellular localization of ZIC3-A and ZIC3-B. ZIC3 isoform expression in HeLa cells was detected by immunohistochemistry using a
mouse anti-FLAG antibody. (A–C) Subcellular localization of ZIC3-A. (D–F) Subcellular localization of ZIC3-B. (G) Quantitative analysis of subcellular
localization. Percentages are representative of at least 100 cell counts each from a minimum of six separate experiments.
doi:10.1371/journal.pone.0023755.g006
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differ in their ability to activate the 12xGLIBS-luc reporter in vitro,
either alone or when co-transfected with GLI3.
When cells were transfected with ZIC3-A or Zic3-B, low level
transcriptional activation was observed compared to baseline
activation, and the level of activation of both isoforms was similar
(Figure 7). As expected, the ZIC3-S43X mutant was not able to
independently activate transcription due to absence of all NLS
domains; however, activation was unexpectedly observed upon co-
transfection with GLI3. As expected based on previous work [3],
increased activation was also seen when ZIC3-A was co-
transfected with GLI3 compared to activation with ZIC3-A alone.
Interestingly, Zic3-B and GLI3 co-transfections did not result in
additional activation compared to Zic3-B alone (Figure 7). Taken
together with previous studies, these results indicate that ZIC3-A
and GLI3 may be transcriptional co-activators [3,6]. In contrast,
although Zic3-B can induce low level transcriptional activation
through the GLIBS alone, it does not co-activate with GLI3.
Screening a heterotaxy and CHD cohort for mutations in
ZIC3-B
Although heterotaxy is more common in males, our previous
analysis indicated that mutations in ZIC3-A were not responsible
for this overrepresentation. To investigate the contribution of
mutations in the novel ZIC3-B isoform we performed mutation
screening in heterotaxy and CHD cohorts (Table 1). De-identified
genomic DNA samples were PCR amplified and sequenced in 109
males, consisting of 5 familial and 104 sporadic cases. Of the 5
familial cases, 2 exhibited a clear X-linked inheritance pattern. No
mutations were identified within exon 4. In addition to screening all
samplesforexon4,sampleswhichhad notbeenpreviouslyanalyzed
for ZIC3-A mutations were sequenced for these exons as well and
no mutations were identified. The mouse model of Zic3 deficiency
results in loss of function of both isoforms of Zic3 and has a very
severe phenotype with a high percentage of gastrulation defects and
early pregnancy loss [2,12]. Therefore, we cannot rule out the
possibility that mutations in exon 4 cause early embryonic lethality
or a distinct phenotype not represented in our heterotaxy cohort.
Discussion
Alternative splicing is a diversification mechanism that allows
for increases in proteome complexity via specific regulation of
gene expression. Splicing may result in different protein domain
combinations, alterations in tissue specificity, or dramatic changes
in functional activity, all of which have profound implications for
development and disease. Here, we demonstrate that a transcrip-
tion factor that is important for proper cardiac development exists
as two distinct isoforms that are expressed in vivo through
alternative splicing at the carboxy terminal domain. Pritsker et
al. [31] previously demonstrated that splicing is often weakly
conserved in orthologous genes in mouse and human. Thus, the
conservation of alternatively spliced ZIC3 isoforms in both human
and mouse cell lines suggests functional importance.
The ZIC3-B isoform retains most of the mapped domains of
ZIC3, including four zinc finger DNA binding domains, two NLS
domains, and the NES domain. Thus previously identified patient
mutations should be re-evaluated in terms of their functional effect
not only on the ZIC3-A isoform, but also on ZIC3-B. Our past
findings suggested that the NES domain of ZIC3 is cryptic, and
that structural changes, possibly at the carboxy terminus, are
required to expose the motif and facilitate export [8]. It will
therefore be important to determine the effect of the novel C-
terminus identified in ZIC3-B on nuclear export. In addition, the
NLS and NES motifs overlap with the zinc fingers of ZIC3, which
have previously been shown to bind GLI [32]. GLI transcription
factors contain a functionally active bipartite NLS motif as well as
an NES, and undergo complex nucleocytoplasmic trafficking in
conjunction with SUFU (Suppressor of fused) to mediate
hedgehog signaling [23,33,34,35,36,37]. Physical interactions
between ZIC3 and GLI may result in the coordination of several
NLS sites for recruitment to the nucleus and/or alteration in
exposure of NES motifs. Studies investigating possible binding
partners, including GLI family members, may provide additional
clues for further understanding the nucleocytoplasmic shuttling
mechanism of ZIC3-A and –B during left-right patterning and
cardiac development.
Studies on GLI superfamily members have also shown that
post-translational modifications are a primary determinant in the
protein’s ability to affect transcription [32,36]. ZIC3 can bind to
consensus GLI binding sites to activate transcription, and ZIC3-A
appears to act as a transcriptional co-activator in conjunction with
GLI3 [3]. The inability of Zic3-B to also act as a transcriptional
co-activator with GLI3 may be due to the previously described
differences in the fifth zinc finger domain and/or third NLS
domain (Figure 2C). More studies are necessary to compare
differences in the C-termini of the two isoforms, the subcellular
localization of both isoforms and GLI3 proteins when co-
transfected, and the effect of potential post-translational modifi-
cations of both isoforms [11].
The data indicate that the developmental and tissue specific
expression profiles of murine Zic3-A and Zic3-B overlap. Previous
studies have shown that alternatively spliced isoforms that are co-
expressedmayactasnegative regulators[38]. Itwill be importantto
examine the co-regulation of the –A and –B isoforms during
development. Our initial mutation analyses did not identify
pathogenic mutations in exon 4. Because of the small number of
familiesavailablefor study,analysisof additional X-linked pedigrees
will be required to establish the prevalence of the alternatively
spliced isoform in familial cases. Given that ZIC3-A mutations have
Figure 7. Transcriptional activation mediated by ZIC3 isoforms.
NIH/3T3 cells were transfected with Flag-GLI3, HA-ZIC3-A, HA-ZIC3-S43X
mutant, or HA-Zic3-B. Transfection of ZIC3-A or Zic3-B alone resulted in
similar levels of transcriptional activation above baseline, but GLI3 or
ZIC3-S43X alone did not result in activation. Co-transfection of ZIC3-A
or ZIC3-S43X with GLI3 resulted in co-activation, but there was no
increase in activation when Zic3-B and GLI3 were co-transfected. ZIC3-A
acts as a co-activator with GLI3 but Zic3-B does not. (*) Significant
difference determined by two-tailed, unpaired Student’s t-test assum-
ing unequal variances.
doi:10.1371/journal.pone.0023755.g007
Identification of a Novel ZIC3 Isoform
PLoS ONE | www.plosone.org 8 August 2011 | Volume 6 | Issue 8 | e23755been identified at relatively low rates (approximately 1%) in
sporadic heterotaxy cases and isolated congenital heart defects,
analysis of exon 4 of the ZIC3-B isoform in larger cohorts is
important to more clearly establish its contribution to disease.
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